Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Oct. 20, 2016

Addex initiates study of ADX-88178 in nonhuman primate model of cocaine addiction

Oct. 11, 2016

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Aug. 19, 2016

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Aug. 17, 2016

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

July 27, 2016

Cerecor announces research grant for the development of CERC-501

July 27, 2016

Cerecor awarded grant from NIAAA

July 21, 2016

Addex Therapeutics reports positive results on ADX-71441

June 10, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.